Attralus Bulletin

News, Press Releases, & Other Media
A purple and cyan fibril graphicA purple and cyan fibril graphic
In the News

Attralus Eyes Further Work on Therapeutic Candidates with New Funding

www.biospace.com
Source Author:

Krystle Vermes

September 14, 2020
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free

California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round. With this funding, Attralus will be able to conduct further work on its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.

Systemic amyloidosis translates into about 30 different disorders that occur in the body as a result of protein misfolding. This produces amyloid fibrils that accumulate in various organs.

California-based biopharmaceutical company Attralus announced today that it has concluded a $25 million Series A financing round. With this funding, Attralus will be able to conduct further work on its pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.

Systemic amyloidosis translates into about 30 different disorders that occur in the body as a result of protein misfolding. This produces amyloid fibrils that accumulate in various organs.

<< Back to Bulletin

Get in Touch

Partnership, Careers, Press, OR PATIENT Inquiries

Thank you

Your message has been received!

We will reply as soon as possible.
Oops! Something went wrong while submitting the form.
A purple and cyan fibril graphic

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.